News

Filter

Current filters:

Cardio-vascularevolocumab

1 to 9 of 14 results

Biologics will complement statins in cholesterol treatment space, says GlobalData

Biologics will complement statins in cholesterol treatment space, says GlobalData

11-11-2014

Biologics will play an influential role in shaping the future of cardiovascular drug treatment, in particular…

alirocumabAmgenCardio-vascularevolocumabMarkets & MarketingPharmaceuticalRegeneronSanofiUSA

Amgen sues Sanofi and Regeneron over alleged patent infringement

19-10-2014

USA-based Amgen has filed a law suit in the US District Court of Delaware against French pharma major…

alirocumabAmgenBiotechnologyCardio-vascularevolocumabLegalPatentsRegeneron PharmaceuticalsSanofiUSA

Amgen files for US approval of cholesterol drug evolocumab

28-08-2014

USA-based Amgen, the world's leading independent biotech firm, has filed a Biologics License Application…

AmgenBiotechnologyCardio-vascularChemistryevolocumabFamilial hypercholesterolemiaHealth Medical PharmaHigh cholesterolPCSK9RegulationUSA

Acute coronary syndrome treatment market to more than triple by 2023

Acute coronary syndrome treatment market to more than triple by 2023

30-07-2014

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary…

Acute coronary syndromealirocumabAmgenBayerCardio-vascularEuropeevolocumabJapanMarkets & MarketingMerck & CoPfizerPharmaceuticalSanofiUSAXareltoZontivity

Amgen’s evolocumab to become gold standard among add-on statin therapies

Amgen’s evolocumab to become gold standard among add-on statin therapies

22-07-2014

Leading independent biotech firm Amgen’s investigational compound evolocumab (AMG-145) is set to become…

AmgenBiotechnologyCardio-vascularCardiovascular diseaseEuropeevolocumabMarkets & MarketingUSA

Evolocumab combined with statin results in further reduction of cholesterol levels

Evolocumab combined with statin results in further reduction of cholesterol levels

14-05-2014

Among patients with high cholesterol receiving moderate- or high-intensity statin therapy, the addition…

AmgenBiotechnologyCardio-vascularevolocumabResearch

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

31-03-2014

USA-based Amgen announced data at the American College of Cardiology 63rd Annual Scientific Session this…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

1 to 9 of 14 results

COMPANY SPOTLIGHT

Menarini

Back to top